MRP Capital Investments LLC Sells 12,850 Shares of Amedisys, Inc. (NASDAQ:AMED)

MRP Capital Investments LLC trimmed its position in Amedisys, Inc. (NASDAQ:AMED) by 97.6% in the fourth quarter, Holdings Channel reports. The fund owned 315 shares of the health services provider’s stock after selling 12,850 shares during the quarter. MRP Capital Investments LLC’s holdings in Amedisys were worth $29,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of AMED. Blue Trust Inc. raised its position in shares of Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after acquiring an additional 124 shares in the last quarter. Xponance Inc. grew its stake in shares of Amedisys by 3.5% in the 4th quarter. Xponance Inc. now owns 4,349 shares of the health services provider’s stock valued at $395,000 after buying an additional 148 shares during the period. Inspire Investing LLC grew its stake in shares of Amedisys by 3.6% in the 4th quarter. Inspire Investing LLC now owns 4,405 shares of the health services provider’s stock valued at $400,000 after buying an additional 155 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Amedisys by 1.2% in the 4th quarter. Nisa Investment Advisors LLC now owns 15,150 shares of the health services provider’s stock valued at $1,375,000 after buying an additional 180 shares during the period. Finally, Retirement Systems of Alabama grew its stake in shares of Amedisys by 0.5% in the 4th quarter. Retirement Systems of Alabama now owns 39,822 shares of the health services provider’s stock valued at $3,615,000 after buying an additional 181 shares during the period. 94.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Stephens restated an “equal weight” rating and issued a $101.00 target price on shares of Amedisys in a research note on Tuesday, March 4th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $100.75.

Amedisys Price Performance

AMED stock opened at $92.77 on Friday. The company has a market capitalization of $3.04 billion, a P/E ratio of 36.81, a price-to-earnings-growth ratio of 1.78 and a beta of 0.76. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The business has a 50-day simple moving average of $92.20 and a two-hundred day simple moving average of $92.67.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). The company had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Research analysts expect that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.